AEGEA raises $13.3m to develop endometrial ablation device
This article was originally published in Clinica
Executive Summary
AEGEA Medical, developer of a novel, minimally-invasive treatment for abnormal uterine bleeding, has completed a $13.3 million private equity financing led by Covidien Ventures and including existing investors Alloy Ventures and Delphi Ventures. Amy Belt, Director of Covidien Ventures, has joined AEGEA's board of directors.